This article has Open Peer Review reports available.
Acute fibrinous and organizing pneumonia associated with influenza A/H1N1 pneumonia after lung transplantation
© Otto et al.; licensee BioMed Central Ltd. 2013
Received: 8 August 2012
Accepted: 8 May 2013
Published: 19 May 2013
Immunocompromised patients, particularly after lung transplantation, are at high risk to develop atypical forms of pulmonary infections including influenza A/H1N1. Acute Fibrinous and Organizing Pneumonia (AFOP) is a special histological pattern in acute respiratory failure with high mortality.
We describe a 66-year-old woman with double lung transplantation in August 2009 due to end stage pulmonary fibrosis. After prolonged weaning and subsequent promising course, she developed atypical pneumonia with diffuse pulmonary infiltrates in both lungs in January 2010. Infection with influenza A/H1N1 virus was verified. The patient rapidly suffered from respiratory insufficiency and died eight days after this diagnosis. The post-mortem revealed especially in the lower parts of the lungs the classical histological pattern of pure AFOP. Molecular analyses of lung tissue were positive for influenza A/H1N1.
To our knowledge we present the first case of AFOP triggered by viral infection, here proven to be influenza virus A/H1N1. Thus, also in the setting of viral infection the highly deadly differential diagnosis of AFOP must be considered.
KeywordsAFOP Influenza A/H1N1 Acute lung failure Lung transplantation Viral infection
Immunocompromised patients, especially after lung transplantation are at high risk to develop atypical pneumonias. Among viral infections, influenza A/H1N1 pneumonia can lead to severe respiratory conditions in this patient group often resulting in deadly respiratory insufficiency. Acute fibrinous and organizing pneumonia (AFOP) is a distinct reaction pattern in acute respiratory failure with high mortality rate of upto 90%. Although some causes of AFOP are known so far, its pure form without the presence of accompanying hyaline membranes typical for diffuse alveolar damage (DAD) has not been described to be linked to viral pneumonias.
The 66-year old caucasian female patient suffered from end-stage pulmonary fibrosis caused by usual interstitial pneumonia (UIP) first diagnosed in November 2004. According to the guidelines of the International Society for Heart and Lung Transplantation, the patient was submitted to double sided lung transplantation in August 2009. Immediate post-operative course was complicated by prolonged respiratory weaning with the necessity of percutaneous tracheotomy. The patient could not be immunized with influenza vaccination due to poor general condition in September and October 2009, the vaccination period for the seasonally expected influenza viruses. In November 2009, the patient was transferred to rehabilitation treatment. During the end of December 2009 and the beginning of January 2010, she complained about persistent cough. Because of aggravation of her general and especially respiratory condition, she was admitted to a local district hospital and, due to respiratory deterioration, subsequent intubation was needed. High-dose corticosteroid therapy was initiated to overcome acute organ rejection. As respiratory insufficiency further deteriorated, she was finally transferred to the intensive care unit of the medical department at the University Medical Center Freiburg.
Nasotracheal secretion was positive for viral influenza A/H1N1 RNA, proved by RT-PCR. Under the working diagnosis of influenza A/H1N1 pneumonia with bacterial superinfection, therapy with meropenem, clarithromycin and oseltamivir was initiated. Because a mutation causing resistance against Oseltamivir was detected.in further PCR work-up, oseltamivir was subsequently switched to zanamivir. Immunosuppressive therapy was continued with prednisolone and mycophenolate-mofetil, while tacrolimus was interrupted due to high serum levels.
Timeline of the clinical course
Diagnosis of usual interstitial pneumonia (UIP)
Double lung transplantation, complicated postoperative course
December 2009 - January 2010
Admission to general hospital
Aggravation of general/ respiratory condition
Admission to intensive care unit
Nasotracheal secretion positive for viral influenza A/H1N1 RNA (working diagnosis: H1N1 pneumonia with bacterial superinfection)
Meropenem, clarithromycin and oseltamivir
Detection of viral influenza A/H1N1 RNA by real-time PCR (bronchoscopy)
Detection of mutation causing resistence against oseltamivir
Switch from oseltamivir to zanamivir
Acute renal failure
Continuous venous-venous hemofiltration
Extracorporeal interventional lung assist implantation
Rapidly progressive respiratory failure
After admission to the medical intensive care unit, bronchoscopy was performed to evaluate initial differential diagnoses of acute graft rejection and infectious pneumonia. Bronchial mucosa was edematous and reddened. Mucus was viscous but not extensive in amount. Surgical anastomoses were inconspicuous. No pus or signs of acute bacterial infection could be observed. Bronchioalveolar lavage (BAL) fluid and sputum were sent to microbiological examination.
In sputum and BAL samples, infection with influenza virus A/H1N1 could be verified four days prior to death by real-time RT-PCR . Multiplex-PCR proved to be negative for other bacterial or viral infections. Accordingly, cytomegalovirus PCR, cell culture assays and bacterial and fungal cultures were negative during her last hospitalisation period at the University Medical Center Freiburg.
Molecular analysis of lung tissue revealed positive results for influenza A/H1N1by PCR. There was no detection of any bacterial or fungal infection in any analysed lung specimen, neither by microbiological nor by histological examination.
Epidemic influenza A/H1N1 originally developed in the United States of America and Mexico in 2009 and finally spread worldwide to a pandemic disease [2, 3]. The first case in Germany was registered in April 2009 . Influenza virus infections may cause serious pulmonary complications with death rates of approximately 7% [5, 6]. Although previously healthy patients may suffer from severe H1N1 infection, mortality proved to be particularly high in patients with predisposing conditions, i.e. obesity, pulmonary diseases, other than asthma or chronic obstructive pulmonary disease, pregnancy or pneumonia .
Patients with primary or secondary immunodeficiencies, particularly patients after lung transplantation are at especially high risk for development of severe pulmonary complications caused by influenza A/H1N1 infections. This, therefore, demonstrates a severe condition in lung transplanted patients [2, 5, 7].
AFOP was first described by Beasley et al.  in 2002 and represents a distinct histological pattern of lung injury related to DAD. Beasley described two forms of AFOP: one less aggressive with good response to corticosteroids, the other with poor clinical outcome and a high mortality rate of 53% . AFOP presents with specific histological features, i.e. patchy intraalveolar fibrin deposits, diffuse organizing pneumonia and absence of hyaline membranes. In the current literature, causes of AFOP are idiopathic or in combination with collagen vascular diseases , bacterial infections  and after certain drug exposure (e.g. amiodarone, abacavir [8, 11], statins  as well as exposure to inhalative agents (e.g. coal mining, construction, zoological work, hairspray) .
One of a newborn child is reported with acute respiratory distress syndrome and AFOP after respiratory syncytial virus pneumonitis . However, histology revealed hyaline membranes in the vicinity of AFOP-patterns, thus classifying it as DAD with focal patterns of AFOP. In contrast, upon autopsy of our patient no hyaline membranes were detected in any tissue sample. Therefore, in the case presented here, pure AFOP in association with viral infection is to be diagnosed.
Concluding, for the first time proof is given that viral agents at least of the myxovirus family - here influenza A/H1N1 - can induce pure often fatal AFOP. Consequently, AFOP in the setting of viral pneumonia must be taken into account especially in immunocompromised patients as successful treatment with a combination of corticosteroids and mycophenolate-mofetil has recently been reported .
Informed and written consent for post-mortem investigation, scientific research and following publication as clinical image was given by the patient prior to death.
The article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding program Open Access Publishing.
- Panning M, Baumgarte S, Laue T, Bierbaum S, Raith S, Drexler JF, Helmer A, Falcone-Kapper V, Kochs G, Campe H: Singleplex real-time RT-PCR for detection of influenza A virus and simultaneous differentiation of A/H1N1v and evaluation of the RealStar influenza kit. J Clin Virol. 2011, 50 (2): 171-174. 10.1016/j.jcv.2010.10.010.View ArticlePubMedGoogle Scholar
- Danziger-Isakov LA, Husain S, Mooney ML, Hannan MM: The novel 2009 H1N1 influenza virus pandemic: unique considerations for programs in cardiothoracic transplantation. J Heart Lung Transplant. 2009, 28 (12): 1341-1347. 10.1016/j.healun.2009.10.001.View ArticlePubMedGoogle Scholar
- Wang X, Yang P, Seale H, Zhang Y, Deng Y, Pang X, He X, Wang Q: Estimates of the true number of cases of pandemic (H1N1) 2009, Beijing, China. Emerg Infect Dis. 2010, 16 (11): 1786-1788. 10.3201/eid1611.100323.View ArticlePubMedPubMed CentralGoogle Scholar
- Poggensee G, Gilsdorf A, Buda S, Eckmanns T, Claus H, Altmann D, Krause G, Haas W: The first wave of pandemic influenza (H1N1) 2009 in Germany: from initiation to acceleration. BMC Infect Dis. 2010, 10: 155-10.1186/1471-2334-10-155.View ArticlePubMedPubMed CentralGoogle Scholar
- Delaney JW, Fowler RA: 2009 influenza A (H1N1): a clinical review. Hosp Pract. 2010, 38 (2): 74-81.Google Scholar
- Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, Semple MG, Read RC, Taylor BL, Brett SJ, McMenamin J: Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax. 2010, 65 (7): 645-651. 10.1136/thx.2010.135210.View ArticlePubMedPubMed CentralGoogle Scholar
- Girard MP, Tam JS, Assossou OM, Kieny MP: The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine. 2010, 28 (31): 4895-4902. 10.1016/j.vaccine.2010.05.031.View ArticlePubMedGoogle Scholar
- Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD: Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med. 2002, 126 (9): 1064-1070.PubMedGoogle Scholar
- Hariri LP, Unizony S, Stone J, Mino-Kenudson M, Sharma A, Matsubara O, Mark EJ: Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: a case report and review of the literature. Pathol Int. 2010, 60 (11): 755-759. 10.1111/j.1440-1827.2010.02586.x.View ArticlePubMedGoogle Scholar
- Heo JY, Song JY, Noh JY, Yong HS, Cheong HJ, Kim WJ: Acute fibrinous and organizing pneumonia in a patient with HIV infection and Pneumocystis jiroveci pneumonia. Respirology (Carlton, Vic. 2010, 15 (8): 1259-1261. 10.1111/j.1440-1843.2010.01845.x.View ArticleGoogle Scholar
- Lee SM, Park JJ, Sung SH, Kim Y, Lee KE, Mun YC, Lee SN, Seong CM: Acute fibrinous and organizing pneumonia following hematopoietic stem cell transplantation. Korean J Intern Med. 2009, 24 (2): 156-159. 10.3904/kjim.2009.24.2.156.View ArticlePubMedPubMed CentralGoogle Scholar
- Spiro SG, Silvestri GA, Aqusti A: Clinical Respiratory Medicine. 2012, Philadelphia: Elsevir Saunders, 4Google Scholar
- Cincotta DR, Sebire NJ, Lim E, Peters MJ: Fatal acute fibrinous and organizing pneumonia in an infant: the histopathologic variability of acute respiratory distress syndrome. Pediatr Crit Care Med. 2007, 8 (4): 378-382. 10.1097/01.PCC.0000269375.10806.60.View ArticlePubMedGoogle Scholar
- Bhatti S, Hakeem A, Torrealba J, McMahon JP, Meyer KC: Severe acute fibrinous and organizing pneumonia (AFOP) causing ventilatory failure: successful treatment with mycophenolate mofetil and corticosteroids. Respir Med. 2009, 103 (11): 1764-1767. 10.1016/j.rmed.2009.07.009.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/13/30/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.